Ozempic Gastroparesis Settlement: Statute of Limitations for Ozempic in Texas

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Specific Exposure Risks

For decades, general health and science communication has served as the foundation for public understanding of medical risks and treatment options. This legacy context emphasized broad awareness of pharmaceutical benefits and side effects, often framed within population-level guidelines. As scientific inquiry deepens, the focus naturally narrows from general health principles to specific exposure scenarios that demand closer scrutiny. In the domain of mass production, where pharmaceuticals are manufactured and distributed at scale, the transition from abstract health information to concrete occupational and consumer exposure becomes critical. The case of Ozempic—a widely prescribed medication for metabolic conditions—illustrates this pivot. While general health discourse once centered on its therapeutic efficacy, emerging attention now turns to the implications of sustained exposure, particularly regarding gastrointestinal complications such as gastroparesis.

Bridging to Ozempic and Gastroparesis in Texas

In Texas, where pharmaceutical distribution and usage are extensive, the legal and medical landscape shifts toward understanding how prolonged exposure may intersect with liability timelines. The statute of limitations for claims related to Ozempic and gastroparesis thus becomes a focal point, bridging the legacy of general health education with the pressing need to address exposure risks in both clinical and manufacturing settings. This transition underscores the evolution from population-level awareness to individualized exposure assessment. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Its pharmacological action delays gastric emptying, a mechanism that can contribute to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has been reported in association with Ozempic use.

Clinical Evidence Linking Ozempic to Gastrointestinal Adverse Events

Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath testing to confirm delayed emptying. The overlap between Ozempic’s known gastrointestinal effects and gastroparesis symptoms raises questions about causation and adequate warning. Evidence from the Ozempic prescribing information indicates that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher with Ozempic (3.1% for 0.5 mg, 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, specific gastrointestinal reactions with a frequency below 5% included dyspepsia (1.9% placebo, 3.5% Ozempic 0.5 mg, 2.7% Ozempic 1 mg), eructation, flatulence, gastroesophageal reflux disease, and gastritis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these tables, the symptoms overlap significantly with the reported adverse events.

Mechanistic Plausibility and Warning Adequacy

Mechanistically, GLP-1 receptor agonists like Ozempic slow gastric emptying by inhibiting vagal nerve activity and reducing antral contractions. This effect is dose-dependent and can persist with chronic use. In susceptible individuals, this pharmacological action may precipitate or exacerbate gastroparesis, leading to prolonged symptoms and potential complications such as malnutrition, dehydration, and electrolyte imbalances. The timeline between Ozempic exposure and documented harm varies. Some patients develop symptoms during dose escalation, while others may experience delayed onset after months of treatment. The prescribing information notes that gastrointestinal adverse reactions are most common during dose escalation, but persistent symptoms may indicate gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Regarding adequacy of warnings, the Ozempic label includes a section on hypersensitivity reactions but does not specifically warn about gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The label mentions gastrointestinal adverse reactions generally and lists dyspepsia, gastroesophageal reflux disease, and gastritis, but gastroparesis is not named. This omission may be significant for patients who develop severe or persistent symptoms.

Statute of Limitations and Settlement Considerations in Texas

For affected patients in Texas, settlement-related considerations depend on the statute of limitations for product liability claims. In Texas, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered. For Ozempic-related gastroparesis, the clock may start when a patient is diagnosed or when symptoms become severe enough to prompt medical evaluation. The timeline between exposure and harm is critical: if symptoms began during dose escalation but were not diagnosed as gastroparesis until later, the discovery rule may apply. Patients should consult with a Texas attorney to determine their specific filing deadline. Settlement considerations also involve the strength of evidence linking Ozempic to gastroparesis. The prescribing information documents a higher incidence of gastrointestinal adverse reactions with Ozempic compared to placebo, and the mechanistic plausibility is supported by the drug’s effect on gastric emptying. However, the label does not explicitly warn about gastroparesis, which could be a factor in failure-to-warn claims. Patients who developed gastroparesis after using Ozempic may need to demonstrate that the drug caused their condition and that the manufacturer did not provide adequate warnings. The availability of settlement funds depends on the number of claims and the manufacturer’s liability. As of now, no nationwide settlement has been announced for Ozempic-related gastroparesis, but individual cases may proceed.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Texas?

In Texas, the statute of limitations for personal injury claims, including product liability, is generally two years from the date the injury was discovered or should have been discovered. For Ozempic-related gastroparesis, this means the clock typically starts when a patient is diagnosed with gastroparesis or when symptoms become severe enough to prompt medical evaluation. The discovery rule may apply if symptoms began during dose escalation but were not diagnosed until later. It is crucial to consult with a Texas attorney to determine the specific filing deadline for your case.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that delays gastric emptying as part of its mechanism of action. Clinical trials show a higher incidence of gastrointestinal adverse reactions such as nausea, vomiting, and dyspepsia in patients taking Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in the prescribing information, the symptoms overlap significantly with reported adverse events, and the drug's effect on gastric emptying provides a plausible link. Patients who develop persistent gastrointestinal symptoms should discuss the possibility of gastroparesis with their healthcare provider.

Has there been a settlement for Ozempic gastroparesis?

As of now, no nationwide settlement has been announced specifically for Ozempic-related gastroparesis. However, individual cases may proceed through litigation. The strength of evidence linking Ozempic to gastroparesis, including the higher incidence of gastrointestinal adverse reactions and the lack of explicit warning about gastroparesis in the label, may influence settlement considerations. Patients should consult with an attorney to evaluate their individual circumstances and potential for compensation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.